Recommendation
Design a drug that disrupts the signaling molecules (e.g., AHLs) involved in quorum sensing to prevent the coordinated expression of biofilm genes. 1, 2
Rationale tied to morbidity, mortality, and QOL: Preventing device-associated P. aeruginosa biofilms lowers bloodstream and device-related infections that drive sepsis, device failure, and deaths; guidelines highlight QS inhibition as a key anti-virulence avenue for preventing biofilm-driven clinical relapse and complications on foreign bodies 1. Recent evidence syntheses emphasize targeting LasR/RhlR/PqsR and AHLs to blunt QS-regulated biofilm and virulence, improving downstream clinical control and antibiotic responsiveness 2.
Why the other options are harmful or counterproductive:
- Enhancing EPS matrix formation increases biofilm tolerance and infection risk (worsens outcomes).
- Inhibiting LPS to increase adhesion promotes early attachment and biofilm seeding.
- Targeting flagellum to increase attachment directly facilitates biofilm initiation.
Implementation priorities (algorithmic):
- Select QS targets: LasR/RhlR/PqsR and their AHL signals (Las/Rhl AHLs) to block coordinated biofilm gene expression 2.
- Optimize competitive antagonists or signal-degrading agents (e.g., AHL analogs/lactonases), validated with in vitro biofilm inhibition and virulence readouts, then in vivo device models to confirm infection reduction relevant to morbidity/mortality 1, 2.
- Plan combination with antibiotics to enhance killing of QS-weakened communities, as antivirulence-QS inhibition can potentiate antibiotics and reduce required doses, improving clinical outcomes and resistance stewardship 1, 2.
Pitfalls/caveats to avoid:
- Single-pathway inhibition may be bypassed due to QS redundancy; favor multi-target QS interference (Las/Rhl/Pqs) and confirm functional biofilm reduction, not just docking affinity 2.
- Do not increase surface adhesion or EPS—both accelerate biofilm establishment and worsen device-associated infection risks.